sonrotoclax + zanubrutinib + rituximab

This triplet combination therapy is a chemotherapy-free regimen designed for the treatment of B-cell malignancies, specifically follicular lymphoma. It combines **sonrotoclax** (BGB-11417), a potent and highly selective second-generation BCL-2 inhibitor; **zanubrutinib** (Brukinsa), a next-generation small molecule inhibitor of Bruton's tyrosine kinase (BTK); and **rituximab**, a chimeric monoclonal antibody targeting the CD20 antigen. By simultaneously inhibiting BCL-2-mediated anti-apoptotic pathways, blocking B-cell receptor (BCR) signaling via BTK, and inducing antibody-dependent cellular cytotoxicity (ADCC) through CD20 binding, the regimen aims to achieve synergistic anti-tumor activity. It is currently being evaluated in the Phase II FLOURISH trial for previously untreated follicular lymphoma patients to improve outcomes and avoid the toxicities associated with traditional chemoimmunotherapy.

Other names

sotoclax + zanubrutinib + rituximabSonrotoclax, Zanubrutinib and RituximabBGB-11417 + BGB-3111 + Rituximab